NEO GENOMICS

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



Brain NGS Fusion Panel

Alternative Name
Brain Tumor Fusion Panel

Methodology
Molecular

Test Description
The Brain Tumor NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ALK, BRAF, C11orf95, EGFR, EGFRvIII, EML4, ETV6, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, ROS1, TACC3, TFG, and YAP1.

Clinical Significance
The Brain Tumor NGS Fusion Panel is intended to detect gene fusions associated with brain tumors to aid in the diagnosis, disease classification, and therapy determination. Gliomas are the most common primary brain tumors with high recurrence and mortality rates. Gene fusions are identified in 30-50% of glioblastomas (GBMs). Potentially druggable gene fusions in all GBMs include FGFR (1.2%-8.3%), EGFR (2.2%-4%), and NTRK (1.2%-1.7%). MET gene fusion (with PTPRZ1) has a 3% rate of incidence, but with an unfavorable prognosis.

Specimen Requirements
- **FFPE tissue:** Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage & Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81445

New York Approved
Yes

Level of Service
Global

Turnaround Time
21 Days

References

1. Xu, T. et al. Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. *Translational Oncology*

(2018) 1, 609-618.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

12701 Commonwealth Dr., Suite 9
Fort Myers, FL 33913
Phone: 886.776.5907/ Fax: 239.768.0711
neogenomics.com

Rev. 102221